September 16, 2025
ISOFOL PRESENTED AT AKTIEDAGARNA
IN SWEDEN ON SEPTEMBER 16
About Isofol
Isofol Medical AB (publ) is a research-based biotechnology company working to improve the prognosis for patients with severe forms of cancer. The company’s drug candidate arfolitixorin aims to increase the effect of first-line standard treatment for several forms of solid tumors and is currently being studied in colorectal cancer, the world’s third most common cancer, where the medical need for better treatments is urgent. A phase Ib/II study is now being conducted with a new dosing regimen that is expected to optimize the effect of the drug candidate. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.
Upcoming Events
- November 12, 2025 - November 12, 2025
Interim report July-September 2025 - February 18, 2026 - February 18, 2026
Year-end report 2025 - May 19, 2026 - May 19, 2026
Interim Report January-March 2026
Media – Lates pressreleases
Isofol Medical AB (publ) publishes interim report, January–June 2025
GOTHENBURG, Sweden, August 26, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report for January–June 2025 is…
Isofol invites to a presentation of the interim report for the second quarter 2025
GOTHENBURG, Sweden, August 21, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites investors, analysts and media to a webcast presentation and…
New number of shares and votes in Isofol
GOTHENBURG, Sweden, July 31, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces new number of shares and votes in the company.The information…
INVESTORS – latest reports and presentations
FOLLOW US
Stay updated on the latest news by
following Isofol on Linkedin.
